-
Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCIHY Wang, RL Gao, KF Dou et al. -
Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS RegistryJoyce LC, Baber U, Mehran R et al.
-
Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical PerspectiveG Tersalvi, L Biasco, GM Cioffi et al.
-
Antibody-Based Ticagrelor Reversal Agent in Healthy VolunteersDL Bhatt, CV Pollack, JS Lee et al.
-
Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary InterventionJD McClure, JC Ramsay , C Berry et al.
-
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding RiskM Valgimigli, E Frigoli, the MASTER DAPT Investigators et al.
-
Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatmentX Zhang, XL Zhang, YL Han et al.
-
Elaborately Engineering a Self-Indicating Dual-Drug Nanoassembly for Site-Specific Photothermal-Potentiated Thrombus Penetration and ThrombolysisZQ Zhao, XB Zhang, HY Zhang et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
